Dr Andrew C Philpott MBBS FRACP

Dr Andrew Philpott is an interventional cardiologist with special interests in coronary intervention, clinical cardiology, and cardiovascular pharmacology.  Dr Philpott joined SA Heart in 2008. 

Andrew graduated in medicine at the University of Adelaide in 1996. He completed undergraduate, and clinical pharmacology training at the Royal Adelaide Hospital, and advanced training in cardiology at the Queen Elizabeth Hospital. He was awarded the Fellow of the Royal Australasian College of Physicians (FRACP) in 2002.

Following PhD studies in cardiovascular pharmacology at the University of Adelaide until 2005, Andrew then spent two years in Canada for coronary angioplasty training during 2006 – 2007 at the University of Calgary, in Alberta.

Andrew’s academic achievements include:

• 2003-2005 Lions Medical Research Scholarship
• 2005 Cardiovascular  Lipid (CVL) Research Grant
• Marjorie Hooper RACP research Scholarship
• 2007 American College of Cardiology, Young Investigator finalist (2nd place)

Andrew returned to Adelaide at the end of 2007 and joined SA Heart.  He consults regularly at the SA Heart clinics at North Adelaide, Ashford, Stirling / MtBarker, St Agnes and Woodville. In addition he is a Senior Staff Cardiologist at the Queen Elizabeth Hospital and Lyell McEwen Hospital.

Publications

1. Philpott AC, Southern DA, Clement FM, Galbraith PD, Traboulsi M, Knudtson ML, Ghali WA. Long-term outcomes of patients receiving drug eluting stents.  CMAJ 2009 Jan 20;180(2):167-74.
2. Philpott AC & Anderson TJ. Reactive Hyperemia and Cardiovascular Risk. ATVB 2007 Oct;27(10):2065-7.
3. Philpott AC, Lonn E, Title LM, Verma S, Buithieu J, Charbonneau F, Anderson TJ. Comparison of New Measures Of Vascular Function to Flow Mediated Dilatation as a Measure of  Cardiovascular Risk Factors. American Journal of Cardiology (in press).
4. Philpott A, Chandy S, Morris R, Horowitz J. Development of a rapid loading regimen for perhexiline in acute coronary syndromes. Internal Medicine Journal 2004Jun;34(6):361-3
5. de la Lande IS, Stepien JM, Philpott AC, Hughes PA, Stafford I, Horowitz JD. Aldehyde dehydrogenase, nitric oxide synthase and superoxide in ex vivo nitrate tolerance in rat aorta. Eur J Pharmacol. 2004 Aug 2;496(1-3):141-9.
6. Mishra K, Sage P, Philpott AC, Zeitz C, Horowitz JD. Coronary angioplasty without onsite cardiac surgery. Intern Med J. 2006 Jul;36(7):458-61.
7. Philpott A, Sage P, Stafford I, Murphy G, de la Lande IS, Stuklis R, Edwards J, Horowitz JD. Dissociation of aldehyde dehydrogenase activity from nitrate effect, bioconversion, and tolerance in humans. JACC. 2007:49(9):A420
8. Philpott A, Kanna R, Limaye S, Jenkins R, Horowitz J. Percutaneous coronary intervention without onsite cardiac surgery 1992 – 2000. JACC. 2002:39(9):314B
9. Philpott A, Stepien J, Chircov Y, Stafford I, Edwards J, Sage P, de la Lande I, Horowitz J. Effects of aldehyde dehydrogenase inhibition on responses to nitroglycerin in human tissues. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 2003:10:144
10. Sanders P, Shakib S, *Philpott A, Bochner F, Tonkin A, Faunt J. Evidence based management of myocardial infarction: a review of current practices in a teaching hospital. Aust NZ J of Med. 1998:28:867.
11. Sanders P, Shakib S, *Philpott A, Bochner F, Tonkin A, Faunt J. Pharmacological therapies underutilised in the aged population with myocardial infarction. Aust NZ J of Med. 2000:30:303.
12. de la Lande I, Stepien J, *Philpott A, Hughes P, Stafford I, Horowitz J. Aldehyde dehydrogenase and nitrate tolerance. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 2003:10:143
    

Return to Our Cardiologists